Applicant

Donald W. Landry

U.S. Serial No.:

Not Yet Known

Filed Page 4

August 28, 2001

requested such that claims 1, 21 and 41-48 will be pending.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone either of them at the number provided below.

No fee, other than the enclosed \$710.00 filing fee, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White

Registration No. 28,678

Spencer H. Schneider

Registration No. 45,923

Attorneys for Applicant(s) Cooper & Dunham, LLP

1185 Avenue of the Americas

New York, New York 10036

(212) 278-0400

Applicant :

Donald W. Landry

U.S. Serial No.: Filed :

Not Yet Known August 28, 2001

Page 5

## Exhibit A

- --41. (Amended) A [DNA encoding] <u>nucleic acid which encodes</u> the catalytic antibody of [any one of] claim 1[-20].--
- --42. (Amended) A [DNA encoding] <u>nucleic acid which encodes</u> the polypeptide of [any one of] claim 21[-40].--
- --43. (Amended) [A] The catalytic antibody of claim 1, wherein the catalytic antibody is humanized [catalytic antibody of any one of claim 1-20].--
- --44. (Amended) [A] The polypeptide of claim 21, wherein the polypeptide is humanized [catalytic single chain antibody of any one of claim 21-40].--
- --45. (Amended) A pharmaceutical composition for decreasing the concentration of cocaine in a subject which comprises an amount of <a href="the-antibody">the</a> antibody of [any one of] claim 1[-40] effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.--
- --46. (Amended) A method of decreasing the concentration of cocaine in a subject which comprises administering to the subject an amount of an the antibody of [any one of] claim 1[-40] effective to degrade cocaine in the subject, so as to thereby decrease the concentration of cocaine in the subject.--
- --47. (Amended) A pharmaceutical composition for treating cocaine overdose in a subject which comprises an amount

DOGHOVEV. CEESCH

Applicant

Donald W. Landry

U.S. Serial No.:

Not Yet Known

Filed Page 6 August 28, 2001

of the antibody of [any one of] claim 1[-40] effective to degrade cocaine in the subject and a pharmaceutical acceptable carrier.--

--48. (Amended) A method for treating cocaine overdose in a subject which comprises administering to the subject an amount of the antibody of [any one of] claim 1[-40] effective to degrade cocaine [in a subject and reduce cocaine overdose in the subject] , so as to thereby treat cocaine overdose in the subject.--